Skip to main
LFMD

LifeMD (LFMD) Stock Forecast & Price Target

LifeMD (LFMD) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LifeMD is well positioned for growth in the telehealth industry with a diverse portfolio of brands, partnerships with major pharmaceutical companies and a focus on women's health. However, potential challenges include intense competition and potential difficulties in retaining patients. The recent partnership with Hims & Hers Health and the introduction of a new obesity treatment could drive revenue growth, but potential risks may affect their projected 12-month price target of $10.

Bears say

LifeMD is a relatively new company heavily focused on expanding their market through investments in new products and technologies. Despite their potential growth, there are concerns about their reliance on a single segment, as well as potential regulatory actions surrounding the use of peptides. Additionally, there are risks involved with the telemedicine industry, including cybersecurity threats and product recalls, which could hinder their growth. While the company has recently turned EBITDA-positive and has seen impressive growth, there is still uncertainty surrounding their future success in the highly regulated healthcare market.

LifeMD (LFMD) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LifeMD (LFMD) Forecast

Analysts have given LifeMD (LFMD) a Strong Buy based on their latest research and market trends.

According to 7 analysts, LifeMD (LFMD) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LifeMD (LFMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.